Cargando…

Breast Carcinoma After Ocrelizumab Therapy in Multiple Sclerosis Patients: A Case Series and Literature Review

Ocrelizumab is a humanized CD20 monoclonal antibody which was approved for management of Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS) in 2017. We present 2 patients, a 67-year-old woman with history of PPMS and a 42-year-old woman with RRMS, who wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelsey, Andrew, Casinelli, Gabriella, Tandon, Medha, Sriwastava, Shitiz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419566/ https://www.ncbi.nlm.nih.gov/pubmed/34497472 http://dx.doi.org/10.1177/11795735211037785

Ejemplares similares

A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies
por: Kataria, Saurabh, et al.
Publicado: (2020)

Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis
por: Beard, Katherine, et al.
Publicado: (2021)

New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review
por: Sriwastava, Shitiz, et al.
Publicado: (2020)

Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination
por: Podury, Sanjiti, et al.
Publicado: (2021)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

A Novel Case of Bifacial Diplegia Variant of Guillain-Barré Syndrome Following Janssen COVID-19 Vaccination
por: Prasad, Apoorv, et al.
Publicado: (2021)

West Nile virus encephalitis: A report of two cases and review of neuroradiological features
por: Bailey, Christopher, et al.
Publicado: (2020)

Relevance of CSF, Serum and Neuroimaging Markers in CNS and PNS Manifestation in COVID-19: A Systematic Review of Case Report and Case Series
por: Podury, Sanjiti, et al.
Publicado: (2021)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Overcoming the Elusiveness of Neurosarcoidosis: Learning from Five Complex Cases
por: Feizi, Parissa, et al.
Publicado: (2021)

Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series
por: Sriwastava, Shitiz, et al.
Publicado: (2021)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

Acute transverse myelitis with Dysautonomia following SARS-CoV-2 infection: A case report and review of literature
por: Moreno-Escobar, Maria Camila, et al.
Publicado: (2021)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series
por: De Mercanti, Stefania F., et al.
Publicado: (2021)

Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature
por: Au, Michael, et al.
Publicado: (2022)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau, Jessica, et al.
Publicado: (2018)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
por: Garcia-Cañibano, Beatriz, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

Viral pericarditis following ocrelizumab in a multiple sclerosis patient
por: Miele, Giuseppina, et al.
Publicado: (2023)

The spectrum of psychosis in multiple sclerosis: a clinical case series
por: Gilberthorpe, Thomas G, et al.
Publicado: (2017)

Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies
por: Feng, Jenny J, et al.
Publicado: (2017)

COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2
por: Sriwastava, Shitiz, et al.
Publicado: (2021)

Relevance and Clinical Significance of Magnetic Resonance Imaging of Neurological Manifestations in COVID-19: A Systematic Review of Case Reports and Case Series
por: Chowdhary, Anisa, et al.
Publicado: (2020)

Spectrum of Neuroimaging Findings in Post-COVID-19 Vaccination: A Case Series and Review of Literature
por: Sriwastava, Shitiz, et al.
Publicado: (2021)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
por: Daniels, K., et al.
Publicado: (2020)

Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab
por: Gingele, Stefan, et al.
Publicado: (2019)

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
por: Wolinsky, Jerry S, et al.
Publicado: (2020)

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
por: Sempere, Angel P., et al.
Publicado: (2021)

Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
por: Fernandez‐Diaz, Eva, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4ksqinne6qhdugnh1bs4j36i6m